Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non–small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non–small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

Published:2024-04 Issue: Volume: Page:
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Lee Jay M.

Publisher

Elsevier BV

Reference31 articles.

1. Perioperative durvalumab for resectable non–small-cell lung cancer;Heymach;N Engl J Med,2023

2. Perioperative pembrolizumab for early-stage non–small-cell lung cancer;Wakelee;N Engl J Med,2023

3. LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC;Cascone;Ann Oncol,2023

4. Perioperative toripalimab plus chemotherapy for patients with resectable non–small cell lung cancer: the Neotorch randomized clinical trial;Lu;JAMA,2024

5. LBA58 pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial;Yue;Ann Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3